查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006478

人源化小鼠和大鼠模型市场：按模型类型、应用、最终用户和人类细胞划分－2026-2032年全球市场预测

Humanized Mouse & Rat Model Market by Model Type, Application, End User, Human Cell - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人源化小鼠和大鼠模型市场价值将达到 2.9724 亿美元，到 2026 年将成长至 3.1757 亿美元，到 2032 年将达到 4.9448 亿美元，复合年增长率为 7.54%。

主要市场统计数据
基准年 2025 2.9724亿美元
预计年份：2026年 3.1757亿美元
预测年份 2032 4.9448亿美元
复合年增长率 (%) 7.54%

专家概述了人源化小鼠和大鼠模型的创新如何改变前临床开发平臺和转化研究重点。

人源化小鼠和大鼠模型已成为现代非临床研究中不可或缺的工具，为免疫学、感染疾病、肿瘤学、神经病学和心血管科学等领域的转化研究提供了重要依据。这些基因改造和患者来源的模型系统透过提供生理适宜的环境，日益弥合体外研究结果与临床现实之间的差距，从而检验人类特异性免疫相互作用、病原体亲和性和肿瘤生物学特性。随着实验目标的日益复杂，研究人员和产品开发人员需要更高保真度的模型、更可靠的表征手段和更完善的服务，以缩短获得可操作资料的时间并提高实验结果的可重复性。

基因组工程、PDX（患者衍生模型）能力和综合服务交付的进步如何重新定义转化价值和实验可重复性。

由于技术、操作和科学领域各方力量的融合，人源化囓齿动物模型的格局正在经历一场变化。首先，精准的基因组工程和先进的免疫移植技术提高了人源化免疫系统和器官特异性表型的保真度，从而能够更准确地评估免疫疗法和生物製药的疗效。同时，患者来源的异质骨移植库的扩充以及冷冻保存技术的进步，维持了肿瘤的异质性和临床相关性，加速了转化肿瘤学计画的进展。

本研究评估了 2025 年关税调整将如何影响临床前研究生态系统内的供应弹性、筹资策略和供应商多元化。

一系列于2025年前后实施的政策调整和关税措施，对依赖专业动物模型及相关实验室材料的机构的供应链和产业计画产生了多方面的影响。对许多终端用户而言，最直接的影响是进口种畜、专用耗材和某些试剂的到货成本增加，促使采购团队与供应商重新谈判合约、合併订单，并优先选择製造地分布在各地的供应商。作为应对措施，一些供应商已采取相应措施，例如转移关键生产过程、尽可能提高国内繁殖能力以及扩大本地库存，以应对更长的前置作业时间週期。

详细的細項分析揭示了模型类型、应用重点、最终用户优先顺序和产品/服务配置如何影响采购和研发选择。

透过按模型类型、应用、最终用户和产品类型分析人源化囓齿动物市场格局，可以为研发规划人员和采购经理提供具体的策略见解。按模型类型划分，该市场包括人源化大鼠模型、免疫力缺乏模型、PDX模型和基因转殖模型。人源化大鼠模型类别包括hACE2和hCD4大鼠模型，它们分别在病毒亲和性研究和免疫肿瘤学研究中特别重要。免疫力缺乏模型进一步包括NOG、NSG和SCID模型，这些模型在移植效率、免疫表型以及对不同异种移植和人体免疫系统重建工作流程的适用性方面存在差异。患者来源的异种移植模型包括乳癌PDX、大肠直肠癌PDX和肺癌PDX，它们提供疾病特异性的保真度，以支持治疗假设检验和生物标记发现。转基因模型用于机制阐明和标靶检验，包括基因敲入模型和基因敲除模型，每种模型在基因功能和路径调控研究中都具有独特的优势。

这项区域比较分析详细说明了美洲、欧洲、中东和非洲以及亚太地区各区域的优势如何影响模型采购、合规性和服务采用。

区域趋势正以不同的方式影响人源化囓齿动物模型的供应能力、调节合作和应用轨迹。美洲地区生物技术中心集中，拥有强大的转化研发管线和成熟的合约研究产业，因此对先进的人源化模型和PDX平台的采用率很高。该地区受益于完善的实验室基础设施和强大的服务供应商网络，这共同降低了进入复杂体内研究计画的门槛，但也面临着与人事费用和监管合规相关的成本压力。相较之下，欧洲、中东和非洲地区呈现异质性格局，杰出的学术机构和专业服务提供者与不同的监管和报销环境并存。这种多样性为跨境合作和专业化细分市场服务创造了机会，但也需要仔细考虑不同的动物福利标准和进出口法规。

深入了解决定临床前服务竞争优势的供应商策略、服务整合、专有模型开发和伙伴关係。

供应商与服务供应商之间的竞争格局呈现出专业化与整合并存的态势，各公司都在追求垂直整合、专有模型库和加值服务包。领先的供应商正增加对冷冻保存的PDX库、先进的表型分析平台和专有的人源化通讯协定的投资，以确保与客户建立长期合作关係，并在技术上脱颖而出。同时，合约研究组织（CRO）正透过策略合作、资本投资和扩大符合GLP规范的设施，拓展其体内研究能力，以支持后期治疗计画。

领导者应采取切实可行的策略步骤来增强供应商的韧性、转化有效性、监管应对力和服务整合能力。

在不断发展的人源化囓齿动物生态系统中，产业领导者可以采取一系列切实可行的措施来增强营运韧性、科学严谨性和商业性地位。首先，应优先考虑供应商合格流程，包括记录繁殖记录、基因检验和移植性能，并将这些标准纳入长期采购合同，从而降低变异性。其次，对于关键模型和试剂，应投资双源采购策略和区域冗余，以减轻政策变化和物流限制带来的干扰，并确保研究进度不受影响。

我们采用透明、多方面的研究途径，结合专家访谈、文件分析和检验检查，为相关人员。

本分析的调查方法结合了结构化的初步研究、严谨的二手资料审查和迭代检验，确保了研究结果的稳健性和实用性。初步资讯透过访谈科学研究负责人、采购经理和合约研究机构（CRO）高阶主管收集，以了解实际决策标准、对前置作业时间的敏感度以及对不断变化的服务的期望。二手资料研究涵盖了同行评审文献、监管指导文件、产品技术文件和营运报告，以揭示技术进步和品质标准。这些定性资讯和文献资料被整合起来，用于建立细分框架、供应链影响情境分析以及跨区域比较评估。

最终的整合突显了科学准确性、供应商合格和营运弹性的整合对于转化研究的成功至关重要。

总之，人源化小鼠和大鼠模型是连结实验生物学和临床应用的关键桥樑，基因工程、PDX模型保存和综合服务交付的持续创新正在重新定义临床前策略。在技​​术进步、监管预期和供应链趋势相互作用的背景下，申办者必须采取更精细的采购、合格和合作方式。随着关税和政策环境的演变，投资于供应商多元化、严格的文件记录和转化检测整合的机构将更有利于保持专案进展势头，并从体内试验中获得更大的预测价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依模型类型分類的人源化小鼠和大鼠模型市场

  • 人源化大鼠模型
    • hACE2 大鼠模型
    • hCD4 大鼠模型
  • 免疫力缺乏模型
    • NOG模型
    • NSG模型
    • SCID模型
  • PDX 型号
    • 乳癌PDX
    • 结肠癌PDX
    • 肺癌PDX
  • 基因改造模型
    • 敲入式模型
    • 淘汰赛模特儿

第九章：人源化小鼠与大鼠模型市场：依应用划分

  • 心血管系统
    • 动脉粥状硬化模型
    • 高血压模型
  • 免疫学
    • 自体免疫疾病模型
    • 发炎性疾病模型
  • 感染疾病
    • 细菌感染模型
    • 病毒感染模型
  • 肿瘤学
  • 细胞疗法试验

第十章：人源化小鼠与大鼠模型市场：依最终使用者划分

  • 学术研究机构
  • 合约研究机构
  • 製药和生物技术公司

第十一章 依人类细胞类型分類的人源化小鼠和大鼠模型市场

  • CD34+干细胞
  • PBMC
  • 患者来源的肿瘤组织（PDX）
  • 诱导性多能干细胞衍生细胞

第十二章：人源化小鼠与大鼠模型市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：人源化小鼠与大鼠模型市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：人源化小鼠与大鼠模型市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国人源化小鼠与大鼠模型市场

第十六章：中国人源化小鼠与大鼠模型市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aragen Life Sciences Ltd.
  • Biocytogen
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Crown Biosciences
  • Cyagen Biosciences
  • GemPharmatech
  • genOway
  • Harbour BioMed
  • Hera BioLabs
  • Ingenious Targeting Laboratory
  • Inotiv
  • Oncodesign Services
  • Ozgene Pty Ltd.
  • Pharmatest Services
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TRANS GENIC
  • TransCure bioServices
  • Vitalstar Biotechnology
Product Code: MRR-961BA04A2E3A

The Humanized Mouse & Rat Model Market was valued at USD 297.24 million in 2025 and is projected to grow to USD 317.57 million in 2026, with a CAGR of 7.54%, reaching USD 494.48 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 297.24 million
Estimated Year [2026] USD 317.57 million
Forecast Year [2032] USD 494.48 million
CAGR (%) 7.54%

An expert overview of how humanized mouse and rat model innovations are reshaping preclinical pipelines and translational research priorities

Humanized mouse and rat models have emerged as indispensable tools in contemporary preclinical research, enabling translational insights across immunology, infectious disease, oncology, neurology, and cardiovascular science. These engineered and patient-derived systems increasingly bridge the chasm between in vitro findings and clinical reality by providing physiologically relevant contexts in which human-specific immune interactions, pathogen tropisms, and tumor biology can be interrogated. As experimental objectives have become more complex, investigators and product developers have demanded higher fidelity models, robust characterization, and integrated service offerings that reduce time to actionable data and enhance reproducibility.

Consequently, suppliers, contract research providers, and academic consortia have expanded their portfolios to include advanced humanized rat variants, a broader range of immunodeficient strains, patient-derived xenograft collections, and precise transgenic constructs. At the same time, improvements in genome editing, breeding, and husbandry, together with enhanced phenotyping and bioassay capabilities, have reshaped how sponsors design preclinical programs. This introduction sets the stage for a deeper analysis of the structural shifts influencing model selection, sourcing strategies, regulatory touchpoints, and end-user preferences, while emphasizing the operational complexities and scientific opportunities that characterize the current landscape.

How advancements in genome engineering, PDX capabilities, and integrated service delivery are redefining translational value and experimental reproducibility

The landscape for humanized rodent models is undergoing transformative shifts driven by converging technological, operational, and scientific forces. First, precision genome engineering and refined immunoengraftment methods have increased the fidelity of humanized immune systems and organ-specific phenotypes, enabling more predictive assessments of immunotherapies and biologics. At the same time, the proliferation of patient-derived xenograft collections and improved cryopreservation practices have accelerated translational oncology programs by preserving tumor heterogeneity and clinical relevance.

Meanwhile, the industry is experiencing a move toward modular service delivery where model provision, efficacy testing, and screening services are bundled to streamline sponsor workflows and reduce administrative friction. Regulatory scrutiny and heightened reproducibility expectations have spurred more rigorous documentation, standardized endpoints, and third-party quality audits. In parallel, computational integration-combining in vivo data with multi-omic readouts and advanced analytics-has emerged as a core capability for unlocking mechanistic insight and optimizing study design. Collectively, these shifts are fostering a more collaborative ecosystem in which cross-disciplinary partnerships, vertical integration, and platform-based approaches define competitive advantage and scientific value.

Assessing how 2025 tariff adjustments shaped supply resilience, procurement strategies, and vendor diversification in preclinical research ecosystems

The cumulative policy adjustments and tariff measures enacted in and around 2025 have exerted a multifaceted impact on supply chains and operational planning for organizations that rely on specialized animal models and contiguous laboratory inputs. For many end users, the immediate effect has been an increase in landed costs for imported breeding stock, specialized consumables, and certain reagents, which has prompted procurement teams to renegotiate supplier agreements, consolidate orders, and prioritize vendors with geographically diversified manufacturing footprints. In response, several providers have adapted by relocating critical production steps, increasing domestic breeding capacity where feasible, and expanding local inventories to buffer against longer lead times.

Beyond direct cost effects, tariffs have influenced decisions about sourcing strategy and vendor selection, reinforcing the importance of contractual flexibility and transparent lead-time commitments. In cases where cross-border logistics became less predictable, sponsors accelerated validation programs for alternative models and suppliers to preserve experimental timelines. Moreover, adjustments in trade policy have elevated compliance requirements and documentation burdens, obliging laboratory and procurement teams to strengthen customs expertise and risk management practices. Taken together, these dynamics have encouraged a shift toward more resilient supply networks, greater emphasis on supplier qualification, and strategic investments in redundancy to protect critical preclinical workflows.

Deep segmentation intelligence revealing how model type, application focus, end-user priorities, and product-service configurations drive procurement and R&D choices

Disaggregating the humanized rodent landscape by model type, application, end user, and product typology reveals targeted strategic implications for R&D planners and procurement leaders. When examined by model type, the market encompasses humanized rat models, immunodeficient models, PDX models, and transgenic models. The humanized rat models category includes hACE2 rat models and hCD4 rat models, which are particularly relevant for viral tropism studies and immuno-oncology investigations respectively. Immunodeficient models further comprise NOG models, NSG models, and SCID models, with variation in engraftment efficiency, immunophenotype, and suitability for diverse xenograft and human immune system reconstitution workflows. Patient-derived xenograft models span breast cancer PDX, colorectal cancer PDX, and lung cancer PDX, offering disease-specific fidelity that supports therapeutic hypothesis testing and biomarker discovery. Transgenic models that are leveraged for mechanistic interrogation and target validation include both knock-in models and knock-out models, each providing distinct advantages for studying gene function and pathway modulation.

Viewed by application, the portfolio aligns with cardiovascular, immunology, infectious disease, neurology, and oncology research needs. Cardiovascular applications include atherosclerosis models and hypertension models that support drug safety and mechanism studies, while immunology applications cover autoimmune disorder models and inflammatory disease models that are critical to biologics development. Infectious disease applications are differentiated into bacterial infection models and viral infection models, a distinction that guides choices around host susceptibility and biosafety. Neurology applications include neurodegenerative disease models and pain models that help translate CNS-targeted therapies, and oncology applications divide into hematological models and solid tumor models depending on tumor microenvironment considerations. End users are typified by academic research institutes, contract research organizations, and pharmaceutical and biotech companies, each adopting different procurement timelines, validation thresholds, and service preferences. Finally, product type distinctions comprise model products and services. Model products are subdivided into commercial models and custom models that address off-the-shelf versus bespoke needs, while services include efficacy testing services, model development services, and screening services that support study execution and translational validation.

Taken together, these segment dimensions indicate that decisions around model selection are increasingly driven by a combination of biological fidelity, service integration, and operational certainty. Sponsors focused on immunotherapies often favor highly characterized immunodeficient strains and tailored humanized constructs, while oncology teams frequently prioritize PDX collections that preserve tumor heterogeneity. Academic institutes are more likely to adopt open-source or academic-sourced models for exploratory work, whereas pharmaceutical and biotech companies emphasize GLP-compliant vendors, reproducible supply chains, and turnkey service packages. Service differentiation-particularly in model development and efficacy testing-has become a principal competitive lever, enabling suppliers to capture longer-term partnerships and reduce transactional friction for complex programs.

Comparative regional analysis detailing how Americas, Europe, Middle East & Africa, and Asia-Pacific differential strengths influence model sourcing, compliance, and service adoption

Regional dynamics shape supply-side capabilities, regulatory interactions, and adoption trajectories for humanized rodent models in distinct ways. In the Americas, a concentration of biotech hubs, strong translational pipelines, and a mature contract research sector support high adoption of advanced humanized constructs and PDX platforms. This region benefits from considerable laboratory infrastructure and a robust service-provider network, which collectively lower barriers to entry for complex in vivo programs, but also face cost pressures related to labor and regulatory compliance. In contrast, Europe, Middle East & Africa displays a heterogeneous landscape where pockets of excellence in academic centers and specialized providers coexist with varied regulatory frameworks and reimbursement environments. This diversity yields opportunities for cross-border collaborations and specialized niche services, yet it also requires careful navigation of differing animal welfare standards and import/export regulations.

The Asia-Pacific region has seen rapid capacity expansion in breeding facilities, CRO services, and translational research hubs, coupled with an increasing number of domestically developed model lines and a growing emphasis on local manufacturing of reagents. As a result, this region offers competitive pricing and scale advantages for sponsors pursuing large preclinical programs, though stakeholders should assess supplier quality systems and documentation to ensure alignment with global regulatory expectations. Across all regions, logistical factors, customs processes, and regional policy shifts influence lead times and supplier selection. Consequently, multinational programs often adopt hybrid sourcing strategies that combine local capacity for routine studies with international partners for highly specialized or validated model systems.

Insights into supplier strategies, service integration, proprietary model development, and partnerships that define competitive advantage in preclinical services

Competitive dynamics among suppliers and service providers are characterized by a mix of specialization and consolidation, as firms pursue vertical integration, proprietary model libraries, and value-added service bundles. Leading providers increasingly invest in cryopreserved PDX banks, advanced phenotyping platforms, and proprietary humanization protocols to secure durable client relationships and create technical differentiation. Parallel to this, contract research organizations are expanding their in vivo capabilities through strategic alliances, capacity investments, and the addition of GLP-compliant facilities to support late-stage therapeutic programs.

Innovation is concentrated around improving engraftment efficiency, reducing xenograft variability, and expanding the repertoire of transgenic constructs tailored to specific mechanistic questions. Providers that excel in quality systems, traceability, and regulatory documentation have a competitive advantage when engaging with large pharmaceutical sponsors who require stringent supplier qualification. In addition, service models that integrate model development, efficacy testing, and biomarker readouts enable suppliers to move up the value chain and capture a greater share of sponsor spend. Finally, partnerships with academic centers and hospital networks are becoming more common, facilitating access to fresh tumor specimens for PDX generation and enabling translational collaborations that accelerate target validation and clinical translation.

Actionable strategic steps leaders should implement to enhance supplier resilience, translational validity, regulatory readiness, and service integration

Industry leaders can adopt a set of pragmatic actions to strengthen operational resilience, scientific rigor, and commercial positioning in the evolving humanized rodent ecosystem. First, prioritize supplier qualification processes that include documentation of breeding records, genetic validation, and engraftment performance, and integrate those criteria into long-term procurement agreements to reduce variability. Second, invest in dual-sourcing strategies and regional redundancy for critical models and reagents in order to mitigate disruptions from policy shifts or logistics constraints, thereby preserving study timelines.

Third, foster internal capabilities for translational assay development and data harmonization so that in vivo findings can be more readily integrated with multi-omic and imaging readouts, increasing the predictive value of preclinical programs. Fourth, negotiate service-level commitments with CRO partners that include clearly defined timelines, contingency plans, and mutual performance metrics to align incentives and reduce downstream delays. Fifth, accelerate the adoption of standardized reporting formats and metadata frameworks across studies to enhance reproducibility and facilitate regulatory engagement. Sixth, pursue strategic collaborations with clinical centers and biobanks to expand access to diverse PDX sources and to enrich translational relevance. Seventh, allocate resources to continuous staff training on animal welfare, biosafety, and regulatory compliance to ensure ethical and high-quality study conduct. Finally, evaluate commercialization opportunities for proprietary models and platform services, balancing licensing potential with the operational demands of scale and quality assurance.

A transparent, triangulated research approach combining expert interviews, documentary analysis, and validation checks to produce reliable strategic insights for stakeholders

The research methodology underpinning this analysis combined structured primary inquiry, rigorous secondary review, and iterative validation to ensure the findings are robust and actionable. Primary inputs included interviews with scientific leaders, procurement managers, and CRO executives to capture real-world decision criteria, lead-time sensitivities, and evolving service expectations. Secondary review encompassed peer-reviewed literature, regulatory guidance documents, technical product literature, and operational reports to map technological trajectories and quality standards. These qualitative and documentary inputs were synthesized to develop a segmentation framework, scenario analyses for supply-chain impacts, and comparative regional assessments.

To validate conclusions, triangulation was employed through cross-referencing interview insights with supplier literature and operational performance indicators, and follow-up consultations were conducted to reconcile divergent perspectives. Quality control procedures included standardized interview guides, source attribution logs, and a reproducibility checklist that documented key assumptions. The methodology acknowledges limitations tied to proprietary supplier data and the rapidly changing policy environment; as such, readers are encouraged to treat the insights as strategic guidance that should be augmented with firm-specific due diligence when making procurement or R&D decisions.

Final synthesis emphasizing why integration of scientific fidelity, supplier qualification, and operational resilience is essential for translational success

In conclusion, humanized mouse and rat models represent a vital nexus between experimental biology and clinical translation, with ongoing innovations in genetic engineering, PDX preservation, and integrated service delivery redefining preclinical strategy. The interplay of technological progress, regulatory expectations, and supply-chain dynamics requires sponsors to adopt more sophisticated procurement, qualification, and collaboration practices. As tariff and policy environments evolve, organizations that invest in supplier diversification, rigorous documentation, and translational assay integration will be better positioned to sustain program momentum and extract higher predictive value from in vivo studies.

Ultimately, the competitive landscape rewards those who combine scientific excellence with operational discipline: firms that can deliver reproducible, well-characterized models alongside turnkey services will capture deeper sponsor engagement and support faster decision making. By applying the segmentation insights, regional considerations, and actionable recommendations provided herein, stakeholders can align their preclinical strategies with scientific priorities and operational realities to accelerate therapeutic development and mitigate risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Humanized Mouse & Rat Model Market, by Model Type

  • 8.1. Humanized Rat Models
    • 8.1.1. hACE2 Rat Models
    • 8.1.2. hCD4 Rat Models
  • 8.2. Immunodeficient Models
    • 8.2.1. NOG Models
    • 8.2.2. NSG Models
    • 8.2.3. SCID Models
  • 8.3. PDX Models
    • 8.3.1. Breast Cancer PDX
    • 8.3.2. Colorectal Cancer PDX
    • 8.3.3. Lung Cancer PDX
  • 8.4. Transgenic Models
    • 8.4.1. Knock-In Models
    • 8.4.2. Knock-Out Models

9. Humanized Mouse & Rat Model Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Atherosclerosis Models
    • 9.1.2. Hypertension Models
  • 9.2. Immunology
    • 9.2.1. Autoimmune Disorder Models
    • 9.2.2. Inflammatory Disease Models
  • 9.3. Infectious Disease
    • 9.3.1. Bacterial Infection Models
    • 9.3.2. Viral Infection Models
  • 9.4. Oncology
  • 9.5. Cell Therapy Testing

10. Humanized Mouse & Rat Model Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Biotech Companies

11. Humanized Mouse & Rat Model Market, by Human Cell

  • 11.1. CD34+ Stem Cells
  • 11.2. PBMC
  • 11.3. Patient Tumor Tissue (PDX)
  • 11.4. iPSC-derived Cells

12. Humanized Mouse & Rat Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Humanized Mouse & Rat Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Humanized Mouse & Rat Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Humanized Mouse & Rat Model Market

16. China Humanized Mouse & Rat Model Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aragen Life Sciences Ltd.
  • 17.6. Biocytogen
  • 17.7. Champions Oncology, Inc.
  • 17.8. Charles River Laboratories
  • 17.9. Crown Biosciences
  • 17.10. Cyagen Biosciences
  • 17.11. GemPharmatech
  • 17.12. genOway
  • 17.13. Harbour BioMed
  • 17.14. Hera BioLabs
  • 17.15. Ingenious Targeting Laboratory
  • 17.16. Inotiv
  • 17.17. Oncodesign Services
  • 17.18. Ozgene Pty Ltd.
  • 17.19. Pharmatest Services
  • 17.20. Taconic Biosciences, Inc.
  • 17.21. The Jackson Laboratory
  • 17.22. TRANS GENIC
  • 17.23. TransCure bioServices
  • 17.24. Vitalstar Biotechnology

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL THERAPY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL THERAPY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL THERAPY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CD34+ STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CD34+ STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CD34+ STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PBMC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PBMC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PBMC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PATIENT TUMOR TISSUE (PDX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PATIENT TUMOR TISSUE (PDX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PATIENT TUMOR TISSUE (PDX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IPSC-DERIVED CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IPSC-DERIVED CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IPSC-DERIVED CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 263. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 275. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)